Opendata, web and dolomites

BRIGHT

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRIGHT project word cloud

Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.

appropriate    avoiding    colours    clinical    appear    industrial    believe    capturing    savings    stages    reduce    liaise    wavelengths    full    combinations    improvements    clearance    damage    experiencing    company    serving    receptors    coloured    100bn    stroboscopic    inducing    decades    sizeable    vital    33    members    market    prior    demonstration    later    hz    light    fadigue    neuro    pandemic    leds    drugs    amyloid    onset    protective    stepping    frequency    ad    cortex    brain    ing    irreversible    representing    stimulate    minimizing    human    while    business    prepare    flickering    shows    core    invasive    instead    accumulation    protected    productization    significantly    approximately    off    strategy    primarily    global    cascade    untap    certification    patent    disease    alternating    dementia    alone    variants    beta    fusion    delay    maturation    triggers    leverage    white    accentuates    alzheimer    neurodegenerative    setup    flashing    stone    ahead    patients    intervention    visual    optoceutics    prevalence    bright    formed    led    roadblocks    optimal    devised    roll    de    colour    founding    risk    route    players    blue    promotes   

Project "BRIGHT" data sheet

The following table provides information about the project.

Coordinator
OPTOCEUTICS APS 

Organization address
address: DIPLOMVEJ 381
city: KONGENS LYNGBY
postcode: 2800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.optoceutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOCEUTICS APS DK (KONGENS LYNGBY) coordinator 50˙000.00

Map

 Project objective

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.

Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.

OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More